A Test for Multiple Binary Endpoints with Continuous Latent Distribution in Clinical Trials

被引:0
|
作者
Takuma Ishihara
Kouji Yamamoto
机构
[1] Gifu University Hospital,Innovative and Clinical Research Promotion Center
[2] Yokohama City University School of Medicine,Department of Biostatistics
关键词
Latent variable; Non-inferiority; Superiority;
D O I
暂无
中图分类号
学科分类号
摘要
In clinical trials, two or more binary responses obtained by dichotomizing continuous responses are often employed as multiple primary endpoints. Testing procedures for multiple binary variables with latent distribution have not yet been adequately discussed. Based on the association measure among latent variables, we provide a statistic for testing the superiority of at least one binary endpoint. In addition, we propose a testing procedure with a framework in which the trial efficacy is confirmed only when there is superiority of at least one endpoint and non-inferiority of the remaining endpoints. The performance of the proposed procedure is evaluated through simulations.
引用
收藏
页码:463 / 480
页数:17
相关论文
共 50 条
  • [21] Recommendations for the primary analysis of continuous endpoints in longitudinal clinical trials
    Mallinckrodt, Craig H.
    Lane, Peter W.
    Schnell, Dan
    Peng, Yahong
    Mancuso, James P.
    DRUG INFORMATION JOURNAL, 2008, 42 (04): : 303 - 319
  • [22] Recommendations for the Primary Analysis of Continuous Endpoints in Longitudinal Clinical Trials
    Craig H. Mallinckrodt
    Peter W. Lane
    Dan Schnell
    Yahong Peng
    James P. Mancuso
    Drug information journal : DIJ / Drug Information Association, 2008, 42 : 303 - 319
  • [23] Blinded continuous monitoring in clinical trials with recurrent event endpoints
    Friede, Tim
    Haring, Dieter A.
    Schmidli, Heinz
    PHARMACEUTICAL STATISTICS, 2019, 18 (01) : 54 - 64
  • [24] Estimating and testing treatment effects on two binary endpoints and association between endpoints in clinical trials
    Wang, WQ
    Woolson, RF
    Clarke, WR
    COMMUNICATIONS IN STATISTICS-SIMULATION AND COMPUTATION, 2005, 34 (03) : 751 - 769
  • [25] A convenient formula for sample size calculations in clinical trials with multiple co-primary continuous endpoints
    Sugimoto, Tomoyuki
    Sozu, Takashi
    Hamasaki, Toshimitsu
    PHARMACEUTICAL STATISTICS, 2012, 11 (02) : 118 - 128
  • [26] Assessing consistency in clinical trials with two subgroups and binary endpoints: A new test within the logistic regression model
    Grill, Susann
    Ring, Arne
    Brannath, Werner
    Scharpenberg, Martin
    STATISTICS IN MEDICINE, 2020, 39 (30) : 4551 - 4573
  • [27] Block response-adaptive randomization in clinical trials with binary endpoints
    Magirr, Dominic
    PHARMACEUTICAL STATISTICS, 2011, 10 (04) : 341 - 346
  • [28] Blinded sample size recalculation in clinical trials with binary composite endpoints
    Sander, Anja
    Rauch, Geraldine
    Kieser, Meinhard
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2017, 27 (04) : 705 - 715
  • [29] Binary surrogate endpoints in clinical trials from the perspective of case definitions
    Hahn, Andreas
    Podbielski, Andreas
    Heimesaat, Markus M.
    Frickmann, Hagen
    Warnke, Philipp
    EUROPEAN JOURNAL OF MICROBIOLOGY AND IMMUNOLOGY, 2021, 11 (01): : 18 - 22
  • [30] ENDPOINTS IN CLINICAL TRIALS
    Priker, R.
    LUNG CANCER, 2009, 64 : S22 - S22